UniSuper Management Pty Ltd Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

UniSuper Management Pty Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 38.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,306 shares of the biopharmaceutical company's stock after purchasing an additional 2,013 shares during the period. UniSuper Management Pty Ltd's holdings in Regeneron Pharmaceuticals were worth $5,204,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $26,000. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ:REGN traded up $5.94 on Wednesday, reaching $622.94. The company had a trading volume of 417,506 shares, compared to its average volume of 676,785. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $68.10 billion, a PE ratio of 16.27, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52-week low of $607.72 and a 52-week high of $1,211.20. The firm's 50 day simple moving average is $681.52 and its 200-day simple moving average is $788.06.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.57%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on REGN shares. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday. Finally, BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.